The traditional medicine and phytoconstituents from natural products for liver disease: A review
To combat a variety of liver ailments medicinal plants may serve as a vital source because of presence of pharmacologically active phytoconstituents. It is very interesting to note that there is no drug available in the modem system of medicine for treating hepatic disorders; only certain herbal preparations are available to treat this quite vulnerable disease. A large number of plants with hepatoprotective activity are present but only handful of herbs have such scientific support. Herbal medicines have been used to alleviate liver disorders for many centuries and have currently become a favorable therapy for pathological liver disease.
Keywords: Liver disease, Herb, Hepatoprotective activity
2. Crellin, JK. Social validation: an historian’s look at complementary/ alternative medicine. Pharm. Hist, 2011; 31:43-51.
3. Shaw D, Risks or remedies? Safety aspects of herbal remedies. J. Roy. Soc. Med, 1998; 91:294-296
4. Prakash P, Gupta N, Therapeutic Uses of Ocimum sanctum Linn (Tulsi) with a Note on Eugenol and Its Pharmacological Actions: A Review, Indian Journal of Physiology and Pharmacology, 2005; 49:125-131.
5. Akinyemi K O, Oladapo O, Okwara CE, Ibe C C, Fasure KA, Screening of crude extracts of six medicinal plants used in South-West Nigerian unorthodox medicine for anti-methicillin resistant Staphylococcus aureus activity, BMC Complement Altern Med, 2005; 5: 6.
6. Chauhan C et al,Germination, emergence, and dormancy of Mimosa pudica, Weed Biology and Management, 2009; 9(1):38-45.
7. WHO, Traditional Medicine. Fact sheet, 2002; 134.
8. Bhat TA et al, Traditional Use 0f Medicinal Plants by Gujjar And Bakerwal Tribes in Pir Panjal Range of the Shopian District Kashmir India, Advances in Bioresearch, 2003; 3:74 - 80.
9. Griffiths C, Rooney C, Brock A, Leading causes of death in England and Wales how should we group causes? Health statistics quarterly, 2005; 28:6-17.
10. Holt MP, Cynthia JU, Mechanism of drug-induced liver injury, The AAPS Journal, 2006; 8(1):48-54.
11. Nadeem MPC, Dandiya PC, Pasha M, Imran D, Balani K, Vohora SB, Hepatoprotective activity of Solanum nigrum fruits, Fitoterapia, 1997; 68(3):245-51.
12. Negi AS, Kumar JK, Luqman S, Shanker K, Gupta MM, Khanuja SP, Recent advances in plant hepatoprotectives: a chemical and biological profile of some important lead, Medicinal Research Reviews, 2008; 28:821.
13. Handa SS, Sharma A, Chakraborti KK, Evolution of Indian herbal Hepatoprotective Drugs, Fitoterpia, 1986; 57(5):307-51.
14. S. Caldwell and C. Argo, The natural history of non-alcoholic fatty liver disease, Digestive Diseases, 2010; 28:162-168.
15. C. P. de Oliveira, E. S. de Mello, V. A. F. Alves, S. M. Saviero, E. Strauss, Changes in histological criteria lead to different prevalences of nonalcoholic steatohepatitis in severe obesity, Annals of Hepatology, 2007; 6:255–261
16. Ahmad A, Ahmad R, Resveratrol mitigate structural changes and hepatic stellate cell activation in N0 -nitrosodimethylamine-induced liver fibrosis via restraining oxidative damage, Chem Biol Interac, 2014; 221:1-12.
17. Singh V, Visen P.K, Patnaik G.K, Effect of Picroliv on low density lipoprotein receptor binding of rat hepatocytes in hepatic damage induced by paracetamol, Indian Journal of Biochemistry and Biophysics,1992; 29:428-432.
18. Wagner H, Seligmann O, Seitz M, Abraham D, and Sonnenbichler, J. Silydianin Silychristin, zwei isomere Silymarine aus Silybum marianum (Mariendistel), Z Naturforsch, 1976; 31:876-884.
19. Vaknin Y, Hadas R, Schafferman D, Murkhovsky L, Bashan N, The potential of milk thistle (Silybum marianum L), an Israeli native as a source of edible sprouts rich in antioxidants Int J Food Sci Nutr, 2007; 20:1-8.
20. Dehmlow C, Erhard J, de Groot H, Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin, Hepatology, 1996; 23:749–754,
21. Féher J, Lengyel G. Silymarin in the prevention and treatment of liver diseases and primary liver cancer, Curr Pharm Biotechnol, 2012; 13(1):210-217.
22. Luper S. A review of plants used in the treatment of liver disease: Altern Med Rev, 1998; 3:410-21.
23. Agency for Healthcare Research and Quality. Milk thistle: effects on liver disease and cirrhosis and clinical adverse effects. Summary, evidence report/technology assessment: number 21, September 2000.
24. Ahmad N, Mukhtar H. Green tea polyphenols and cancer; bio-364 logic mechanism and practical implications, Nutr Rev, 1999; 57(365):378-383
25. Chen JH, Tipoe GL, Liong EC, So HS, Leung KM, et al, Green tea polyphenols prevent toxin-induced hepatotoxicity in mice by down-regulating inducible nitric oxide-derived prooxidants, Am J ClinNutr, 2004; 80:742-751.
26. Lambert JD, Kennett MJ, Sang S, Reuhl KR, Ju J, et al, Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice, Food ChemToxicol, 2010; 48:409-416.
27. Trivedi NP, Rawal UM, Hepatoprotective and antioxidant property of Andrographis paniculata (Nees) in BHC-induced liver damage in mice, Indian J Exp Biol, 2001; 39:41-46.
28. Shukla B, Visen PK, Patnaik GK, Dhawan BN, Choleretic effect of andrographolide in rats and guinea pigs, Planta Med, 1992; 58:146-149.
29. Yamamura Y, Kotaki H, Tanaka N, Aikawa T, Sawada Y, and Iga, T, The pharmacokinetics of glycyrrhizin and its restaurative effect on hepatic function in patients with chronic hepatitis and in chronically carbon-tetrachloride-intoxicated rats, Biopharm Drug Dispos, 1997; 18:717-725.
30. Van Rossum, T.G, Vulto, A.G, De Man, R.A, Brouwer, J.T, and Schalm, S.W, Review article: glycyrrhizin as a potential treatment for chronic hepatitis C, Aliment Pharmacol Ther, 1998; 12:199-205.
31. Wang, J.Y, Guo, J.S, Li, H, Liu, S.L, and Zern, M.A, Inhibitory effect of glycyrrhizin on NF-kappa B binding activity in CCL4-plus ethanol-induced liver cirrhosis in rats Liver, 1998; 18:180-185.
32. Acharya SK, Dasarathy S, Tandon A, Yoshi YK, Tandon BN, A preliminary open trial on interferon stimulator (SNMC) derived from glycyrrhiza glabra in the treatment of subacute hepatic failure, Ind J Med Res, 1993;98:69-74.
33. Calixto, J.B, Santos, A.R.S, Filbo, V.C, and Yunes, R.A, A review of the plants of the genus Phyllanthus: their chemistry, pharmacology, and therapeutic potential. Med Res Rev, 1998; 18:225-258
34. Venateswaran, P.S, Millman, I, and Blumberg, B.S, Effects of an extract from Phyllanthus niruri on hepatitis B virus and woodchuck hepatitis viruses: in vitro and in vivo studies, Proc Natl Acad Sci USA, 1987; 84:274-278
35. Van Rossum TG, Vulto AG, de Man RA, Brouwer JT, Schalm SW, Glycyrrhizin as a potential treatment for chronic hepatitis C. Alimentary Pharmacology & Therapeutics, 2003; 12(3):199-205.
36. Lahon K, Das S, Hepatoprotective activity of Ocimum sanctum alcoholic leaf extract against paracetamol-induced liver damage in Albino rats. Pharmacognosy Res, 2011; 3:13-18.
37. Baliga MS, Jimmy R, Thilakchand KR, Sunitha V, Bhat NR, Saldanha E, Rao S, Rao P, Arora R, Palatty PL, Ocimum sanctum L (Holy Basil or Tulsi) and its phytochemicals in the prevention and treatment of cancer. Nutr Cancer, 2013; 65(1):26-35.
38. Singh S, Taneja M, Majumdar DK, Biological activities of Ocimum sanctum L. fixed oil an overview, Indian J Exp Biol, 2007; 45:403-412.
39. Wagner H, Seligmann O, Liver therapeutic drugs from Silybummarianum. In: Chang HM, Yeung HW, Tso WW, Koo A, editors. Advances in Chinese Medicinal Materials Research. 1985
40. Visen P.K, Shukla B, Patnaik G.K, Prevention of galactosamine induced hepatic damage by picroliv : study on bile flow and isolated hepatocytes (exvivo), Planta Medica, 1993; 59:37-41.
41. Akila G, Rajakrishnan V, Vishwanathan P, Rajshekaran K.N, Menon V.P, Effects of curcumin on lipid profile and lipid peroxidation status in experimental hepatic fibrosis, Hepatology Research, 1998; 11:147-157.
42. Gupta P.S, Gupta G.D, Sharma M.L,Veno-occlusive disease of liver, British Medical Journal, 1963; 1:1184-1186.
43. Takeda R, Morimoto S, Uchida K, Nakai T, Miyamoto M, Hashiba T, Yoshimitsu K, Kim S, Miwa U, Prolonged pseudoaldosteronism induced by glycyrrhizin, Endocrinologia Japonica, 1979; 6:541-547.
44. Liu J, Pharmacology of oleanolic acid and ursolic acid, Journal of Ethnopharmacology, 1995; 49:57-68.
45. Chiang L.C, Ng L.T, Liu L.T, Shieh D.E, Lin C.C, Cytotoxicity and anti-hepatitis b virus activities of saikosaponins from bupleurum species, Planta Med, 2003; 69:705-709.
46. Mao Y, Zhang J, Hou L, Cui X,The effect of beta-elemene on alpha-tubulin polymerization in human hepatoma hepg2 cells, Chin. J. Cancer Res, 2013; 25:770-776.
47. Malek M.A, Hoang M.H, Jia Y, Lee J.H, Jun H.J, Lee, D.H, Lee H.J, Lee C, Lee M.K, Hwang B.Yet al, Ombuin-3-o-beta-d-glucopyranoside from gynostemma pentaphyllum is a dual agonistic ligand of peroxisome proliferator-activated receptors α and δ/β, Biochem Biophys Res Commun, 2013; 430:1322-1328.
48. KimuraY, Sumiyoshi M, Anti-tumor and anti-metastatic actions of wogonin isolated from scutellaria baicalensis roots through anti-lymphangiogenesis, Phytomed. Int. J. Phytother Phytopharmacol, 2013; 20:328-336.
49. Rao KS, Mishra SH, Antihepatotoxic activity of monomethyl fumarate isolated from Fumaria indica, J. Ethnopharmacol, 1998; 60(3):207-213.
50. Wu JB, Lin WL, Hsieh CC, Ho HY, Tsay HS, Lin WC, The hepatoprotective activity of kinsenoside from Anoectochilus formosanus, Phytother. Res, 2007; 21(1):58-61.
51. Park EJ, Zhao YZ, Young HK, Jung JL, Dong HS, Acanthoic acid from Acanthopanax koreanum protects against liver injury induced by tert-butyl hydroperoxide or carbon tetrachloride in vitro and in vivo, Planta Med, 2004; 70(4):321-327.
52. Singh B, Saxena AK, Chandan BK, Bhardwaj V, Gupta VN, Suri OP, Handa SS. Hepatoprotective activity of indigtone: A bioactive fraction from Indigofera tinctoria Linn, Phytother Res, 2001; 15(4):294- 297.
53. Yoshikawa M, Xu F, Morikawa T, Ninomiya K, Matsuda H, Anastatins A and B, new skeletal flavonoids with hepatoprotective activities from the desert plant Anastatica hierochuntica, Bioorg. Med. Chem. Lett, 2003; 13(6):1045-1049.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).